What diseases and tumors is Trabectedin mainly used to treat?

Trabectedin is an anti-tumor drug derived from marine organisms. It is mainly used to treat specific types of soft tissue sarcoma (STS). Soft tissue sarcomas are rare malignant tumors that originate from muscle, fat, blood vessels, or connective tissue and are difficult to treat, especially when the disease is unresectable or has metastasized. Trabectedin interferes with the transcription and repair mechanism of tumor cell DNA by binding to the minor groove of DNA, thereby preventing cancer cell proliferation and inducing apoptosis, making it one of the important options for the treatment of soft tissue sarcoma.

Clinically, trabectedin is most commonly used in patients with unresectable or metastatic liposarcoma and/or leiomyosarcoma, especially for patients who have previously received anthracycline-containing chemotherapy regimens with limited efficacy. For these patients, trabectedin provides a new treatment approach that can play a role in delaying disease progression and improving quality of life. Its unique mechanism of action allows it to still show certain anti-tumor activity even when traditional chemotherapy drugs are ineffective or resistant.

The use of trabectedin is usually accompanied by strict therapeutic monitoring. Due to its chemotherapeutic properties, patients usually need to undergo blood routine, liver and kidney function and cardiac function evaluation before receiving trabectedin treatment to assess tolerance and safety. During treatment, patients may experience side effects such as bone marrow suppression, liver function abnormalities, fatigue or nausea, so physicians will adjust the dose and perform periodic monitoring based on individual conditions. Scientific and standardized medication management not only helps to exert the efficacy of trabectedin, but also minimizes the risk of adverse reactions.

In addition, trabectedin has also shown long-term efficacy in some refractory sarcoma patients in global multi-center clinical studies, providing clinicians with more basis for treatment options.

Reference materials:https://www.drugs.com/monograph/trabectedin.html